Supreme Court Upholds Mailing of Abortion Pills in 7-2 Vote

The U.S. Supreme Court has issued a 7-2 decision upholding federal regulations that allow the mailing of mifepristone, an FDA-approved medication used for early pregnancy termination. The ruling rejects an emergency challenge brought by anti-abortion advocates and sets aside a previous order from the 5th Circuit Court of Appeals that sought to ban the distribution of these pills via mail. Justices Clarence Thomas and Samuel Alito Jr. dissented, with Justice Alito arguing that the decision undermines the Dobbs v. Jackson Women’s Health Organization precedent, which returned abortion regulation authority to individual states. This legal victory is considered a significant setback for opponents who claim the medication is unsafe, despite the FDA’s long-standing approval and recent regulatory relaxations initiated during the pandemic. The case will now return to the lower courts for further review while the FDA continues its own assessment of the drug's safety protocols. Medication abortions currently account for nearly two-thirds of all abortions in the United States, making access to telehealth services and mail-order prescriptions a critical component of reproductive healthcare availability nationwide.